schwit1 shares a report from UPI: The most popular theory of the moon's origins contends the satellite was formed when a Mars-sized object collided with Earth, vaporizing large portions of Earth's upper crust. While Earth's upper crust is poor in metals, new research -- published Wednesday in the journal Earth and Planetary Science Letters -- suggests the moon's subsurface is surprisingly metal-rich, undermining the satellite's proposed origin story. Authors of the new study suggest planetary scientists consider alternative theories for the moon's formation.

It's possible the collision that forged the moon was more violent than scientists thought, gouging out even deeper portions of Earth's crust and mantle. It's also possible the moon experienced an unusual cool-down process, post-collision -- a process that left the moon with large concentrations of metal.

China has confirmed one case of bubonic plague in northern province Inner Mongolia, according to a statement on the local health authority's website. From a report: The patient is now under treatment at a hospital and is in a stable condition, the Bayannur health commission said in a late Sunday night statement. It also issued a level-three alert, warning of the risks of human-to-human infection and urging citizens to report dead animals, suspected plague cases and patients running a fever for unidentified reasons. Bubonic plague, also called the 'Black Death,' killed 50 million people in a 14th century outbreak in Europe and about 12 million globally in the 19th century. It's now the most common type of plague and can be treated with antibiotics.

Inner Mongolia reported four cases in November while Madagascar sees some cases nearly every year between the months of September and April. Mongolia also confirmed two cases of bubonic plague earlier this month, triggering a quarantine in the province that borders China and Russia. While the ailment is treatable, unlike the novel pathogen which has caused the ongoing pandemic, Chinese health authorities are wary of any infectious disease spreading after a hard-fought containment of the coronavirus outbreak.

A stretch of DNA linked to Covid-19 was passed down from Neanderthals 60,000 years ago, according to a new study. From a report: Scientists don't yet know why this particular segment increases the risk of severe illness from the coronavirus. But the new findings, which were posted online on Friday and have not yet been published in a scientific journal, show how some clues to modern health stem from ancient history. "This interbreeding effect that happened 60,000 years ago is still having an impact today," said Joshua Akey, a geneticist at Princeton University who was not involved in the new study. This piece of the genome, which spans six genes on Chromosome 3, has had a puzzling journey through human history, the study found. The variant is now common in Bangladesh, where 63 percent of people carry at least one copy. Across all of South Asia, almost one-third of people have inherited the segment.

Elsewhere, however, the segment is far less common. Only 8 percent of Europeans carry it, and just 4 percent have it in East Asia. It is almost completely absent in Africa. It's not clear what evolutionary pattern produced this distribution over the past 60,000 years. "That's the $10,000 question," said Hugo Zeberg, a geneticist at the Karolinska Institute in Sweden who was one of the authors of the new study. One possibility is that the Neanderthal version is harmful and has been getting rarer over all. It's also possible that the segment improved people's health in South Asia, perhaps providing a strong immune response to viruses in the region.

Tesla is building mobile molecule printers to produce a potential COVID-19 vaccine being developed in Germany by CureVac, reports Reuters: CureVac, an unlisted German company, has said it is developing portable, automated mRNA production units that it calls printers and which Musk described as "RNA microfactories". They are being designed to be shipped to remote locations, where they can churn out its vaccine candidate and other mRNA-based therapies depending on the recipe fed into the machine. But for the immediate pandemic use — should its vaccine candidate win market approval — it has production sites with regulatory approval in Germany with a capacity to produce hundreds of millions of doses. The company, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, is a pioneer of the so-called messenger RNA approach, which is also pursued by BioNTech and its partner Pfizer as well as Moderna....

The "microfactories" would be built at Tesla Grohmann Automation in Germany, Musk said in a Twitter thread late on Wednesday night.

"Six months into a pandemic that has killed over half a million people, more than 200 scientists from around the world are challenging the official view of how the coronavirus spreads," reports the Los Angeles Times: The World Health Organization and the U.S. Centers for Disease Control and Prevention maintain that you have to worry about only two types of transmission: inhaling respiratory droplets from an infected person in your immediate vicinity or — less common — touching a contaminated surface and then your eyes, nose or mouth.

But other experts contend that the guidance ignores growing evidence that a third pathway also plays a significant role in contagion.

They say multiple studies demonstrate that particles known as aerosols — microscopic versions of standard respiratory droplets — can hang in the air for long periods and float dozens of feet, making poorly ventilated rooms, buses and other confined spaces dangerous, even when people stay six feet from one another. "We are 100% sure about this," said Lidia Morawska, a professor of atmospheric sciences and environmental engineering at Queensland University of Technology in Brisbane, Australia. She makes the case in an open letter to the WHO accusing the United Nations agency of failing to issue appropriate warnings about the risk. A total of 239 researchers from 32 countries signed the letter, which is set to be published next week in a scientific journal.

In interviews, experts said that aerosol transmission appears to be the only way to explain several "super-spreading" events, including the infection of diners at a restaurant in China who sat at separate tables and of choir members in Washington state who took precautions during a rehearsal... The proponents of aerosol transmission said masks worn correctly would help prevent the escape of exhaled aerosols as well as inhalation of the microscopic particles. But they said the spread could also be reduced by improving ventilation and zapping indoor air with ultraviolet light in ceiling units.
The Times also got a response from Dr. Benedetta Allegranzi, a top WHO expert on infection prevention and control, who argued the group only presented theories based on experiments rather than actual evidence from the field.

Allegranzi also added that in weekly teleconferences, a large majority of a group of more than 30 international experts advising the WHO had "not judged the existing evidence sufficiently convincing to consider airborne transmission as having an important role in COVID-19 spread."

"The World Health Organization announced Saturday that it discontinued its trial on hydroxychloroquine's effect on COVID-19 patients in hospitals," reports UPI: WHO said in a statement that it accepted a recommendation from the Solidarity Trial's International Steering Committee that it stop the testing of the drug. The decision to cease the trial came after interim trial results showed that the anti-malaria drug had little or no reduction in mortality of patients hospitalized for the novel coronavirus...

The National Institute of Health similarly halted a hydroxychloroquine trial last month after a study showed no harm or benefit from the anti-malaria drug's use in hospitalized COVID-19 patients. Last month, British researchers similarly found no benefit of hydroxychloroquine.

"A surprising new study found the controversial antimalarial drug hydroxychloroquine helped patients better survive in the hospital," reports CNN. "But the findings, like the federal government's use of the drug itself, were disputed." A team at Henry Ford Health System in southeast Michigan said Thursday their study of 2,541 hospitalized patients found that those given hydroxychloroquine were much less likely to die. Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March. "Overall crude mortality rates were 18.1% in the entire cohort, 13.5% in the hydroxychloroquine alone group, 20.1% among those receiving hydroxychloroquine plus azithromycin, 22.4% among the azithromycin alone group, and 26.4% for neither drug," the team wrote in a report published in the International Journal of Infectious Diseases.

It's a surprising finding because several other studies have found no benefit from hydroxychloroquine, a drug originally developed to treat and prevent malaria...

"Our results do differ from some other studies," Zervos told a news conference. "What we think was important in ours ... is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid," he added. The Henry Ford team also monitored patients carefully for heart problems, he said...

Researchers not involved with the study were critical. They noted that the Henry Ford team did not randomly treat patients but selected them for various treatments based on certain criteria. "As the Henry Ford Health System became more experienced in treating patients with COVID-19, survival may have improved, regardless of the use of specific therapies," Dr. Todd Lee of the Royal Victoria Hospital in Montreal, Canada, and colleagues wrote in a commentary in the same journal. "Finally, concomitant steroid use in patients receiving hydroxychloroquine was more than double the non-treated group. This is relevant considering the recent RECOVERY trial that showed a mortality benefit with dexamethasone." The steroid dexamethasone can reduce inflammation in seriously ill patients...

Eli Rosenberg [lead author of a New York study of hydroxychloroquine], also pointed out that the Detroit paper excluded 267 patients — nearly 10% of the study population — who had not yet been discharged from the hospital. He said this might have skewed the results to make hydroxychloroquine look better than it really was.

"There's a little bit of loosey-goosiness here in all this," he told CNN.

An anonymous reader quotes Ars Technica: On Sunday morning, local time in New Zealand, Rocket Lab launched its 13th mission. The booster's first stage performed normally, but just as the second stage neared an altitude of 200km, something went wrong and the vehicle was lost...

"We lost the flight late into the mission," said Peter Beck, the company's founder and chief executive, on Twitter. "I am incredibly sorry that we failed to deliver our customers satellites today. Rest assured we will find the issue, correct it and be back on the pad soon."

The mission, dubbed "Pics Or It Didn't Happen," carried 5 SuperDove satellites for the imaging company Planet, as well as commercial payloads both for Canon Electronics and In-Space Missions. "The In-Space team is absolutely gutted by this news," the company said after the loss. Its Faraday-1 spacecraft hosted multiple experiments within a 6U CubeSat. "Two years of hard work from an incredibly committed group of brilliant engineers up in smoke. It really was a very cool little spacecraft."
The article notes that since January of 2018, "the company had rattled off a string of 11 successful missions and emerged as a major player in the small satellite launch industry."

In a video statement on Twitter, company founder Peter Beck said solemnly that "Today's issue is a reminder that space flight can be very unforgiving."

"If your family's Fourth of July fireworks plans are up in smoke because of the pandemic, watch the sky for a lunar eclipse instead," reports CNN.

It begins in just 5 minutes -- and then lasts for two hours and 45 minutes: On July 4, just after 11 p.m. ET, the moon will begin its temporary new look. For exactly two hours and 45 minutes, the moon will pass through the feathered outer shadow cast from Earth, creating a partial penumbral lunar eclipse.

A penumbral lunar eclipse occurs when the moon passes through the faint penumbra shadow cast by Earth. The moon misses the Earth's umbral shadow, which is best known for creating total and partial lunar eclipses. This event might not be as illustrious as a partial or total lunar eclipse where parts of the moon seem to disappear. Still, a noticeable darkening of the moon's surface will be visible without a telescope.

The eclipse will begin at 11:07 p.m. ET and last through 1:52 a.m. ET, with peak darkening occurring just after midnight.
The article also notes that every night this summer will see "a great meeting of planets, known by astronomers as a conjunction... Expect a brighter than usual illumination of the planets as they take center stage across the horizon."

While Jupiter will be 15 times brighter than Saturn, they'll both be approaching their closest approach to Earth in 20 years — which finally happens in mid-July.

"They've been up there about a month now, floating around on the International Space Station, keeping tabs on their ride home," reports the Washington Post: "Certainly, the highlight for both Doug and I was the initial arrival at space station, coming through the hatch again and being on board after several years of working on a new spacecraft," Behnken said in an interview from the station this week. Since then, he has performed two spacewalks with Cassidy, successfully replacing batteries on the outside of the station... Now, NASA and the astronauts are turning their focus to the return trip. At the moment, the space agency says the soonest Behnken and Hurley could return is Aug. 2.

If all goes well, the Dragon would undock from the station, fire its thrusters and descend through the atmosphere. The entire mission is a test to see how SpaceX's Dragon capsule performs, and while NASA said its ascent went flawlessly, there still are many risks ahead. As it plunges down, the thickening air will cause friction and generate enormous heat, testing the capsule's heat shield. Then the spacecraft's parachutes are to deploy to slow the vehicle further. SpaceX has struggled with its parachute designs in the past, however. "Parachutes are way harder than they look," Elon Musk said in an interview with The Post before the launch. "The Apollo program actually had a real morale issue with the parachutes because they were so damn hard. They had people quitting over how hard the parachutes were. And then you know we almost had people quit at SpaceX over how hard the parachutes were. I mean they soldiered through, but, man, the parachutes are hard."

Another risk will be landing in the ocean. American astronauts have not splashed down in the water since 1975 — the Space Shuttles landed on land, as do the Russian Soyuz spacecraft. Behnken said he and Hurley expect to spend about an hour bobbing on the ocean surface before they are hoisted on the deck of a ship. SpaceX has been training extensively for the recovery mission, working to get the astronauts to safety as quickly as possible, but that will also be a key test.

"A new study found low to moderate drinking may improve cognitive function for White middle-aged or older adults," reports CNN: The findings support prior research which found that, generally, one standard drink a day for women and two a day for men -- which is the US guidance -- appears to offer some cognitive benefits... "There is now a lot of observational evidence showing that light to moderate alcohol drinking is associated with better cognitive function and a lower risk of dementia compared with alcohol abstaining," said senior principal research scientist Kaarin Anstey, a director of the NHMRC Dementia Centre for Research Collaboration in Australia, who was not involved in the study...

The new study, published Monday in JAMA Network Open, analyzed data on nearly 20,000 participants from the University of Michigan's Health and Retirement Study, a longitudinal panel study that surveys a representative sample of Americans on a variety of health issues. Study participants, who were predominately white, female and a mean age of 62, were given cognitive tests starting in 1996 through 2008, and were surveyed every other year for approximately nine years. When compared with those who said they never drank, low to moderate drinking was associated with significantly higher cognition scores for mental status, word recall and vocabulary over time, as well as with lower rates of decline in each of those areas.
But before you get too excited, CNN has a "However..." paragraph: However, a major global study released last year found that no amount of liquor, wine or beer is safe for your overall health. It found that alcohol was the leading risk factor for disease and premature death in men and women between the ages of 15 and 49 worldwide in 2016, accounting for nearly one in 10 deaths... "What we know for sure is that drinking too much alcohol definitely harms the brain in a major way. What is less clear is whether or not low to moderate intake may be protective in certain people, or if total abstinence is the most sound advice," said neurologist Dr. Richard Isaacson, founder of the Alzheimer's Prevention Clinic at NewYork-Presbyterian and Weill Cornell Medical Center. "Based on conflicting studies, I don't think at this time we can know for sure whether none versus low to moderate consumption is best in each individual person..."

"American consumers pay significantly more for cellphone service than people in many other countries," reports the New York Times.

It's in an article headlined "The U.S. Is Lagging Behind Many Rich Countries. These Charts Show Why." Although executives' salaries have risen in most countries, relative to those of workers, in recent decades, the trend is more extreme in the U.S... The minimum wage is higher in other countries than it is in much of the United States... In addition to minimum wage, the United States has done less to combat rising corporate concentration. Large U.S. companies are better able to hold down the wages of workers, who don't always have good employment options, and are also able to charge higher prices because of less competition...

Arguably the biggest outlier is the American health care system. Prices for drugs, medical procedures and doctors' visits are all substantially higher in the United States than in other countries... In all, Americans pay almost twice as much on average for medical care as citizens of other rich countries. And as you may remember from the opening chart in this article, Americans are far from the world's healthiest people...

The middle class and poor receive a smaller share of national income in the U.S. than in much of Europe, while the rich receive a greater share. If anything, these statistics understate American exceptionalism on inequality, because Americans also work longer hours for their pay than workers in many other places.

The World Health Organization (WHO) should soon get results from clinical trials it is conducting of drugs that might be effective in treating COVID-19 patients, its Director General Tedros Adhanom Ghebreyesus said on Friday. From a report: "Nearly 5,500 patients in 39 countries have so far been recruited into the Solidarity trial," he told a news briefing, referring to clinical studies the U.N. agency is conducting. "We expect interim results within the next two weeks." The Solidarity Trial started out in five parts looking at possible treatment approaches to COVID-19: standard care; remdesivir; the anti-malaria drug touted by U.S. President Donald Trump, hydroxychloroquine; the HIV drugs lopinavir/ritonavir; and lopanivir/ritonavir combined with interferon. Earlier this month, it stopped the arm testing hydroxychloroquine, after studies indicated it showed no benefit in those who have the disease, but more work is still needed to see whether it may be effective as a preventative medicine. Mike Ryan, head of the WHO's emergencies programme, said it would be unwise to predict when a vaccine could be ready against COVID-19, the respiratory disease caused by the novel coronavirus that has killed more than half a million people. Earlier this week, the WHO also warned the some countries may have to reinstate lockdowns as coronavirus pandemic accelerates.

A team of astronomers has discovered what they think are the rocky innards of a giant planet that's missing its thick atmosphere. Their findings have been published in the journal Nature. The BBC reports: Its radius is about three-and-a-half times larger than Earth's but the planet is around 39 times more massive. In this size range, the planet would be expected to have a significant component that's gas. Yet it has a density similar to Earth, appearing to be mostly rocky. The object, called TOI 849 b, was found circling a star much like the Sun that's located 730 light-years away. The core orbits so close to its parent star that a year is a mere 18 hours and its surface temperature is around 1,527C. Researchers aren't sure whether the core lost its atmosphere in a collision or just never developed one.

If it was once similar to Jupiter, there are several ways it could have lost its gaseous envelope. These could include tidal disruption, where the planet is ripped apart from orbiting too close to its star, or even a collision with another planet late in its formation. If it's a "failed" gas giant, this could have occurred if there was a gap in the disc of gas and dust that it emerged from, or if it formed late, after the disc ran out of material.

Excerpt of a paper on Arxiv [PDF]: Citations are often used as a metric of the impact of scientific publications. Here, we examine how the number of downloads from Sci-hub as well as various characteristics of publications and their authors predicts future citations. Using data from 12 leading journals in economics, consumer research, neuroscience, and multidisciplinary research, we found that articles downloaded from Sci-hub were cited 1.72 times more than papers not downloaded from Sci-hub and that the number of downloads from Sci-hub was a robust predictor of future citations. Among other characteristics of publications, the number of figures in a manuscript consistently predicts its future citations. The results suggest that limited access to publications may limit some scientific research from achieving its full impact.

In 2021, Israeli startup Redefine Meat plans to launch a 3D printer that will allow customers to produce plant-based flank steak at home. Engadget reports: Redefine Meat says that through 3D printing, it's able to create plant-based meat with the same "appearance, texture and flavor of animal meat," according to its website. Texture specifically seems to be the 3D printer's hallmark achievement. "You need a 3D printer to mimic the structure of the muscle of the animal," Redefine Meat CEO Eshchar Ben-Shitrit told Reuters.

3D printing differs from other methods companies have used for reproducing meat taste and texture. Both Impossible Foods and Beyond Meat use combinations of plant-based proteins, oils and binders, like methylcellulose and potato starch, to achieve a realistic texture for their ground beef and patties -- though the texture of ground beef is arguably easier to achieve than that of steak. Atlast Food uses mushroom fibers to emulate animal tissue in its meatless bacon.

The U.S. has bought up virtually all the stocks of remdesivir, perhaps the most closely watched experimental drug to treat COVID-19. The Guardian reports: Remdesivir, the first drug approved by licensing authorities in the U.S. to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead's production for July and 90% of August and September. "President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19," said the U.S. health and human services secretary, Alex Azar. "To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people."

The drug, which was trialled in the Ebola epidemic but failed to work as expected, is under patent to Gilead, which means no other company in wealthy countries can make it. The cost is around $3,200 per treatment of six doses, according to the US government statement. The deal was announced as it became clear that the pandemic in the U.S. is spiralling out of control. Anthony Fauci, the country's leading public health expert and director of the National Institute of Allergy and Infectious Diseases, told the Senate the U.S. was sliding backwards.

Thelasko shares a report from the BBC: For every person testing positive for antibodies, two were found to have specific T-cells which identify and destroy infected cells. This was seen even in people who had mild or symptomless cases of Covid-19. But it's not yet clear whether this just protects that individual, or if it might also stop them from passing on the infection to others.

Researchers at the Karolinksa Institute in Sweden tested 200 people for both antibodies and T-cells. Some were blood donors while others were tracked down from the group of people first infected in Sweden, mainly returning from earlier affected areas like northern Italy. This could mean a wider group have some level of immunity to Covid-19 than antibody testing figures, like those published as part of the UK Office for National Statistics Infection Survey, suggest. It's likely those people did mount an antibody response, but either it had faded or was not detectable by the current tests. And these people should be protected if they are exposed to the virus for a second time.

Astronomers are perplexed by the unexplained disappearance of a massive star located 75 million light years away. From a report: A decade ago, light from this colossal star brightened its entire host galaxy, which is officially known as PHL 293B and is nicknamed the Kinman Dwarf. But when scientists checked back in on this farflung system last summer, the glow of the star -- estimated to be roughly 100 times more massive than the Sun -- had been extinguished. The head-scratching discovery was announced in a study published on Tuesday in the Monthly Notices of the Royal Astronomical Society. "We were quite surprised when we couldn't find the star," said lead author Andrew Allan, a PhD student at Trinity College Dublin, in a call. "It is a very extreme star, and it has quite a strong wind, so we can distinguish it from the galaxy. That's what we couldn't see in the newer observations."

The mysterious series of events began when Allan and his colleagues imaged the Kinman Dwarf in August 2019, using the ESPRESSO instrument at the Very Large Telescope in Chile. The team initially set out to learn more about massive stars located in galaxies with low metal densities. Given that the starlit Kinman Dwarf had been observed by other astronomers between 2001 and 2011, the team knew that it would be a good target for their research. "Not a lot is understood about stars in those kinds of environments, so that was the main reason we wanted to look," Allan said. "We are interested in massive stars at the end of their lives in those kinds of environments, so we were really just hoping to get a better resolution observation."

AmiMoJo shares a report from The Guardian: An ambitious project to chart the seabed by 2030 could help countries prepare for tsunamis, protect marine habitats and monitor deep-sea mining. But the challenge is unprecedented. The race officially kicked off in 2017 at the United Nations Ocean Conference in New York City. When it began, around 6% of the ocean was mapped in accurate detail. On June 21, the global initiative -- known formally as the Nippon Foundation-Gebco Seabed 2030 Project -- released its latest edition: it has now mapped one-fifth of the seafloor.

Few countries need accurate maps of the seabed more than Japan, an island nation whose future is uniquely intertwined with the ocean's, and it is the Nippon Foundation , a Japanese non-profit organization run on the gambling proceeds of motorboat racing, that is backing Seabed 2030 with $2m every year. [...] But the mapping is a truly global collaboration, public and free to use, divided among four regional centers. The Alfred Wegener Institute in Germany took the Southern Ocean; Stockholm University and the University of New Hampshire cover the North Pacific and Arctic; New Zealand's National Institute of Water and Atmospheric Research are responsible for the South and West Pacific Ocean. That leaves the largest swath, the entire Atlantic and Indian Oceans, to the Lamont-Doherty Earth Observatory at Columbia University -- Ferrini's team. The finished map itself is created by a fifth centre, based in the UK: the British Oceanographic Data Centre in Southampton. It collects the analyzed data from the four centers and compiles it in the General Bathymetric Chart of the Oceans (Gebco). The data is in the public domain, free to use, adapt and commercially exploit.